Determination of 6-thioguanine and 6-methylmercaptopurine metabolites in renal transplantation recipients and patients with glomerulonephritis treated with azathioprine

Therapeutic Drug Monitoring

Volumn 21, Issue 2, 1999, Pages 231-237

  Chrzanowska, Maria ^a   Krzymański, Maciej ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

6 Methylmercaptopurine metabolites; 6 Thioguanine nucleotides; Allopurinol; Azathioprine; Glomerulonephritis; Renal transplantation

Indexed keywords

6 METHYLTHIOINOSINE; ALLOPURINOL; AZATHIOPRINE; TIOGUANINE;

ADOLESCENT; ADULT; ANEMIA; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DETERMINATION; DRUG HYPERSENSITIVITY; DRUG METABOLISM; FEMALE; GLOMERULONEPHRITIS; GRANULOCYTOPENIA; HEPATOSPLENOMEGALY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; KIDNEY TRANSPLANTATION; LEUKOCYTE COUNT; LEUKOPENIA; MALE; PRIORITY JOURNAL; THROMBOCYTOPENIA;

6-MERCAPTOPURINE; ADULT; ALLOPURINOL; ANTIMETABOLITES; AZATHIOPRINE; ERYTHROCYTES; FEMALE; GLOMERULONEPHRITIS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; THIOGUANINE;

EID: 0344286478     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199904000-00015     Document Type: Article

References (32)

1. Murray JE, Merrill JP, Harrison H, et al. Prolonged survival of human kidney homografts by immunosuppressive drug therapy. N Engl J Med 1963;268:1315-23.
2. Balsløv JT, Brun C, Birger Jensen K, et al. Cytostatic treatment of glomerular diseases. Effect of azathioprine on serum creatinine and proteinuna. Acta Med Scand 1973;193:483-91.
3. Haesslein HC, Pierce JC, Lee HM, et al. Leukopenia and azathioprine management in renal homotransplantation. Surgery 1972;71: 598-604.
4. Lennard L, Van Loon JA, Weinshilboum RM. Pharmacogenetics of acute azathioprine toxicity: Relationship to thiopurine methyltransferase genetic polymorphism. Clin Pharmacol Ther 1989;46: 149-54.
5. Schütz E, Gummert J, Mohr F, et al. Azathiopnne-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient. Lancet 1993;341:436.
6. Soria-Royer C, Legendre C, Mircheva J, et al. Thiopurine methyltransferase activity to asses azathioprine myelotoxicity in renal transplant recipients. Lancet 1993;341:1593-4.
7. Ohlman S, Albertioni F, Peterson C. Day-to-day variability in azathioprine pharmacokinetics in renal transplant recipients. Clin Transplant 1994;8:217-23.
8. Schütz E, Gummert J, Mohr FW, et al. Should 6-thioguanine nucleotides be monitored in heart transplant recipients given azathiopnne? Ther Drug Monit 1996;18:228-33.
9. Krzymański M. Immunosuppressive drugs monitoring in renal transplant recipients. Probl Ther Monit 1993;3:145.
10. Elion GB, Hitchings GH, Azathioprine. In: Sartorelli AC, Johns DG, eds. Handbook of experimental pharmacology. Berlin: Springer-Verlag, 1975:404-25.
11. Chalmers AH, Knight PR, Atkinson MR. Conversion of azathioprine into mercaptopurine and mercaptoimidazole derivatives in vitro and during immunosuppressive therapy. Aust J Exp Biol Med Sci 1967;45:681-91.
12. Chrzanowska M, Muszalska I. Azathioprine conversion to 6-mercaptopurine in quantitative azathioprine determination in plasma. Chem Anal 1996;41:103-11.
13. Van Scoik KG, Johnson CA, Porter WR. The pharmacology and metabolism of the thiopurine drugs 6-mercaptopurine and azathioprine. Drug Metab Rev 1985;16:157-74.
14. Tidd DM, Paterson ARP. A biochemical mechanism for the delayed cytotoxic reaction of 6-mercaptopurine. Cancer Res 1974; 34:738-46.
15. Lennard L. The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol 1992;43:329-39.
16. Lennard L, Van Loon JA, Lilleyman JS, et al. Thiopurine pharmacogenetics in leukemia: Correlation of erythrocyte thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations. Clin Pharmacol Ther 1987;41:18-25.
17. Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: Monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980;32:651-62.
18. Ohlman S, Lindholm A, Liliemark J, et al. Large interindividual variability in bioavailability of azathioprine in renal transplant recipients. Clin Transplant 1993;7:65-70.
19. Chocair PR, Duley JA, Simmonds HA, et al. The importance of thiopurine methyltransferase activity for the use of azathioprine in transplant recipients. Transplantation 1992;53:1051-6.
20. Snow JL, Gibson LE. The role of genetic variation in thiopurine methyltransferase activity and the efficacy and/or side effects of azathioprine therapy in dermatologic patients. Arch Dermatol 1995;131:193-7.
21. Lennard L. Assay of 6-thioinosinic acid and 6-thioguanine nucleotides, active metabolites of 6-mercaptopurine, in human red blood cells. J Chromatogr 1987;423:169-78.
22. Lennard L, Singleton HJ. High-performance liquid chromatographic assay of the methyl and nucleotide metabolites of 6-mercaptopurine: Quantitation of red blood cell 6-thioguanine nucleotide, 6-thioinosinic acid, and 6-methylmercaptopurine metabolites in a single sample. J Chromatogr 1992;583:83-90.
23. Schmiegelow K, Bruunshuus I. 6-Thioguanine nucleotide accumulation in red blood cells during maintenance chemotherapy for childhood acute lymphoblastic leukemia, and its relation to leukopenia. Cancer Chemother Pharmacol 1990;26:288-92.
24. Schütz E, Gummer J, Armstrong VW, et al. Azathioprine pharmacogenetics: the relationship between 6-thioguanine nucleotides and thiopurine methyltransferase in patients after heart and kidney transplantation. Eur J Clin Chem Clin Biochem 1996;34:199-205.
25. Zimm S, Collins JM, O'Neill D, et al. Inhibition of first-pass metabolism in cancer chemotherapy: Interaction of 6-mercaptopunne and allopurinol. Clin Pharmacol Ther 1983;34:810-17.
26. Lennard L, Brown CB, Fox M, et al. Azathioprine metabolism in kidney transplant recipients. Br J Clin Pharmacol 1984;18:693-700.
27. Chan GL, Erdmann GR, Gruber SA, et al. Azathioprine metabolism: pharmacokinetics of 6-mercaptopurine, 6-thiouric acid and 6-thioguanine nucleotides in renal transplant patients. J Clin Pharmacol 1990;30:358-63.
28. Lennard L, Lilleyman JS. Individualizing therapy with 6-mercaptopurine and 6-thioguanine related to the thiopurine methyltransferase genetic polymorphism. Ther Drug Monit 1996;18:328-34.
29. Burton NK, Barnett MJ, Aherne GW, et al. The effect of food on the oral administration of 6-mercaptopurine. Cancer Chemother Pharmacol 1986;18:90-1.
30. Berkovitch M, Matsui D, Zipursky A, et al. Hepatotoxicity of 6-mercaptopurine in childhood acute lymphocytic leukemia: Pharmacokinetic characteristics. Med Pediatr Oncol 1996;26:85-9.
31. Lennard L, Welch J, Lilleyman JS. Intracellular metabolites of mercaptopurine in children with lymphoblastic leukaemia: A possible indicator of non-compliance? Br J Cancer 1995;72:1004-6.
32. Cuffari C, Theoret Y, Latour S, et al. 6-Mercaptopurine metabolism in Crohn's disease: Correlation with efficacy and toxicity. Gut 1996;39:401-6.